Antinociceptive activity of sodium valproate in mice after chronic treatment

General Pharmacology

Volumn 29, Issue 3, 1997, Pages 463-467

  Abulaban, F S ^a   Dhariwal, M A H ^a   Al Bekairi, A M ^a   Raza, M ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Antinociceptive activity; Carryover effects; Chronic treatment; Sodium valproate

Indexed keywords

VALPROIC ACID;

ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; BODY TEMPERATURE; CONTROLLED STUDY; DRUG WITHDRAWAL; LOCOMOTION; LONG TERM CARE; MALE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ANALGESICS; ANIMALS; BODY TEMPERATURE; MALE; MICE; MOTOR ACTIVITY; PAIN MEASUREMENT; SUBSTANCE WITHDRAWAL SYNDROME; TIME FACTORS; VALPROIC ACID;

EID: 0030840617     PISSN: 03063623     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-3623(96)00471-5     Document Type: Article

References (40)

1. Booker H. (1982) Phenobarbital: relation of plasma concentration to seizure control. In Antiepileptic Drugs, 2nd ed. (Edited by Woodbury D.M., Penry J. K. and Pippenger C. E.) pp. 341-350. Raven Press, New York.
2. Brodie M. J. (1990) Established anticonvulsants and treatment of refractory epilepsy. Lancet 336, 350-354.
3. Chapman A., Keane P. E., Meldrum B. S., Simiand J. and Vernieres J. C. (1982) Mechanism of anticonvulsant action of valproate. Prog. Neurobiol. 19, 315-359.
4. Davis R., Peters D. H. and McTavish D. (1994) Valproic acid: reappraisal of its pharmacological properties and clinical efficacy in epilepsy. Drugs 47(2), 332-372.
5. De-Feudis F. V. (1982) γ-Aminobutyric acid and analgesia. Trends Pharmac. Sci. 3, 444-446.
6. Dhariwal M. A. H., Raza M., Ageel A. M. and Al-Haider A. A. (1996) A study of the antinociceptive activity of sodium valproate in mice. Pharmac. Commun. 7, 189-198.
7. Emrich J. H. M. and Wolf R. (1989) Valproate and mania. In Fourth International Symposium on Sodium Valproate and Epilepsy. (Edited by Chadwick D.) pp. 217-224. Royal Society of Medicine Services, London.
8. Fariello R. and Smith C. M. (1989) Valproate mechanisms of action. In Antiepileptic Drugs, 3rd ed. (Edited by Levy R., Mattson R., Meldrum B., Penry J. K. and Dreifuss F. E.) pp. 567-575. Raven Press, New York.
9. Frey H. H. and Loscher W. (1978) Distribution of valproate across the interface between blood and cerebrospinal fluid. Neuropharmacology 17, 637-642.
10. Guieu R., Mesdjian E., Rochat H. and Roger J. (1993) Central analgesic effect of sodium valproate in patients with epilepsy. Seizure 2, 147-150.
11. Haefely W. (1989) Benzodiazepines: mechanism of action. In Antiepileptic Drugs, 3rd ed. (Edited by Levy R. H., Mattson R., Meldrum B., Penry J. K. and Dreifuss F. E.) pp. 721-734. Raven Press, New York.
12. Harding G. A., Herrick C. E. and Jeavons P. M. (1978) A controlled study of the effects of sodium valproate on photosensitive epilepsy and its prognosis. Epilepsia 19, 555-565.
13. Hering R. and Kruitzky A. (1992) Sodium valproate in the prophylatic treatment of migraine: a double-blind study versus placebo. Cephalgia 12, 81-84.
14. Horton R. W. (1986) GABA, epilepsy and anticonvulsant drugs. In What Is Epilepsy? The Scientific and Clinical Basis of Epilepsy. (Edited by Trimble M. R. and Reynolds E. H.) pp. 281-292. Churchill Livingstone, London.
15. Jensen R., Brinck T. and Olesen J. (1994) Sodium valproate has a prophylactic effect in migraine without aura. Neurology 44, 647-651.
16. Krnjevie K. (1991) Significance of GABA in brain function. In GABA Mechanisms in Epilepsy. (Edited by Tunnicliff G. and Raess B. U.) pp. 47-87. Wiley-Liss, New York.
17. Kutt H. (1982) Phenytoin interactions with other drugs. In Antiepileptic Drugs, 2nd ed. (Edited by Woodbury D. M., Penry J. K. and Pippenger C. E.) pp. 227-240. Raven Press, New York.
18. Lockard J. S. (1980) A primate model of clinical epilepsy: mechanism of action through quantification of therapeutic effects. In Epilepsy: A window to brain mechanisms. (Edited by Lockard J. S. and Ward A. A.) pp. 11-49. Raven Press, New York.
19. Lockard J. S. (1986) Epileptic neurons in clinical epilepsy? evidence from a monkey model with spontaneous paroxysms. In What is Epilepsy? The Scientific and Clinical Basis of Epilepsy. (Edited by Trimble M. R. and Reynolds E. H.) pp. 265-280. Churchill Livingstone, London.
20. Lockard J. S. and Levy R. H. (1976) Valproic acid: reversible acting drug? Epilepsia 17, 477-479.
21. Lockard J. S. and Levy R. H. (1990) Valproate and paroxysmal cyclicity compared to other anticonvulsants in monkey model. In Chronopharmacology in Therapy of Epilepsies. (Edited by Dreifuss F. E., Meinordi H. and Stefan H.) pp. 105-127. Raven Press, New York.
22. Lockard J. S., Levy R. H., Congdom W. C., Ducharme L. L. and Rhodes P. H. (1984) Valproate non-reversibility: dosing procedures critical? In Metabolism of Antiepileptic Drugs. (Edited by Levy R. H., Pitlick W. H., Eichelbaum M. and Meijer J.) pp. 153-167. Raven Press, New York.
23. Loscher W. (1981) Plasma levels of valproic acid and its metabolites during continued treatment in dogs. J. Vet. Pharmoc. Ther. 4, 111-119.
24. Loscher W. (1985) Valproic acid. In Antiepileptic Drugs (Handbook of Experimental Pharmacology, Vol. 74). (Edited by Frey H. H. and Janz D.) pp. 507-536. Raven Press, New York.
25. Loscher W., Bohme G., Schafer H. and Kochen W. (1981) Effects of metabolites of valproic acid on the metabolism of GABA in brain and nerve endings. Neuropharmacology 20, 1187-1192.
26. Loscher W. and Nau H. (1982) Valproic acid: metabolic concentrations in plasma and brain, anticonvulsant activity and effects on GABA metabolism during sub-acute treatment in mice. Arch. Int. Pharmocodyn. 257, 20-31.
27. Loscher W. and Nau H. (1983) Distribution of valproic acid and its metabolites in various brain areas of dogs and rats after acute and prolonged treatment. J. Pharmac. Exp. Ther. 226, 845-854.
28. Loscher W., Nau H. and Siemes H. (1988) Penetration of valproic acid and its active metabolites into cerebrospinal fluid of children with epilepsy. Epilepsia 29, 311-316.
29. Loscher W. and Vetter M. (1985) In vivo effects of aminooxyacetic acid and valproic acid on nerve terminal (synaptosomal) GABA levels in discrete brain areas of the rat. Biochem. Pharmac. 34, 1749-1756.
30. Marsden C. D. (1982) Basal ganglia diseases. In Neurotransmitters and CNS Diseases. A Lancet Review. (Edited by Munroe I.) pp. 21-27. The Lancet Limited, London.
31. Meldrum B. S. (1983) Mechanism of action of anticonvulsant drugs. In Research Progress in Epilepsy. (Edited by Rose F. C.) pp. 333-343. Pitman Press, London.
32. Nau H. and Loscher W. (1984) Valproic acid and metabolites: pharmacological and toxicological studies. Epilepsia 25(Suppl. 1), S14-S22.
33. Patry G. and Naquet R. (1970) Action de l'acide dipropylacetique chez le Papio papio photosensible. Can. J. Physiol. Pharmac. 49, 568-572.
34. Phillips N. and Fowler L. J. (1982) The effects of sodium valproate in γ-aminobutyrate metabolism and behaviourism naive and ethanol amine-o-sulphate pretreated rats and mice. Biochem. Pharmac. 31, 257-261.
35. Rowan A. J., Binnie C. D., Warfield C. A., Meinardi H. and Meijer J. W. A. (1979) The delayed effect of sodium valproate on the photo-convulsive response in man. Epilepsia 20, 61-68.
36. Schechter P. J., Trainer Y. and Grove J. (1978) Effects of n-dipropylacetate on amino acid concentrations in mouse brain: correlation with anticonvulsant activity. J. Neurochem. 31, 1325-1327.
37. Simler S., Ciesielski M., Randrianariosa H. and Mandel P. (1973) Effects of sodium-n-propylacetate on audiogenic seizures and brain aminobutyric acid levels. Biochem. Pharmac. 22, 1701-1708.
38. Sorensen K. V. (1988) Valproate: a new drug in migraine prophylaxis. Acta Neurolog. Scand. 78, 346-348.
39. Ticku M. K. (1991) Mechanism of GABA agonists and modulators of GABAergic transmission in anticonvulsant activity. In GABA Mechanisms in Epilepsy. (Edited by Tunnicliff G. and Raess B. U.) pp. 149-164. Wiley-Liss, New York.
40. Zachariah S. B., Borges E. F., Varghese R., Cruz A. R. and Ross G. S. (1994) Positive response to oral divalproex sodium (Depakote) in patients with spasticity and pain. Am. J. Med. Sci. 308, 38-40.